Systemic Lupus Erythematosus Arthritis
A 29-year-old woman with systemic lupus erythematosus has taken hydroxychloroquine 400 mg daily for 12 months. She has persistent symmetrical swelling of the metacarpophalangeal and proximal interphalangeal joints and wrists with 90 minutes of morning stiffness, and has needed three courses of oral prednisolone this year. Urinalysis shows no protein or casts, complement is normal, and anti-double-stranded DNA is negative. Which is the most appropriate next step in management?
- A.Add oral methotrexateCorrect
- B.Add intravenous cyclophosphamide
- C.Add long-term oral prednisolone 20 mg daily
- D.Replace hydroxychloroquine with colchicine
Explanation
Hydroxychloroquine is the backbone of treatment for every patient with systemic lupus erythematosus, but when musculoskeletal disease remains active despite an adequate trial, a steroid-sparing immunosuppressant is added. For predominantly articular lupus without major organ involvement, methotrexate is the preferred first additional agent, with leflunomide and azathioprine as alternatives and belimumab reserved for persistently active disease. The driving principle is glucocorticoid minimisation: this patient has already needed three prednisolone courses in a year, and cumulative steroid exposure causes osteoporosis, avascular necrosis, diabetes, cataract and infection, which are major sources of long-term damage in lupus. Methotrexate is given weekly with folic acid supplementation, and requires monitoring of liver enzymes and blood counts plus strict contraception because it is teratogenic. Cyclophosphamide is reserved for severe organ-threatening disease such as proliferative lupus nephritis, neuropsychiatric lupus or diffuse alveolar haemorrhage, none of which is present here given a bland urinalysis, normal creatinine and normal complement. Chronic moderate-dose prednisolone treats the symptom while guaranteeing cumulative toxicity, the exact outcome guidelines aim to avoid. Colchicine has no role in lupus arthritis and hydroxychloroquine should never be stopped, since it reduces flares, thrombosis and mortality. Retinal toxicity screening is nonetheless required after 5 years of hydroxychloroquine, or earlier if risk factors exist.
Why each option
- A.
- Correct. Methotrexate is the preferred steroid-sparing agent for lupus arthritis that persists despite hydroxychloroquine, and it is added while hydroxychloroquine is continued.
- B.
- Cyclophosphamide is reserved for organ-threatening lupus such as proliferative nephritis or neuropsychiatric disease; this patient has normal renal function and a bland urinalysis.
- C.
- Long-term moderate-dose prednisolone controls symptoms but accumulates toxicity, and modern guidelines specifically aim to minimise chronic glucocorticoid exposure.
- D.
- Colchicine has no established role in lupus arthritis, and hydroxychloroquine should be continued lifelong because it reduces flares and improves survival.
Reference: EULAR Recommendations for the Management of Systemic Lupus Erythematosus, 2023 Update
This is one of 3,306 questions in the MedBoardSA SMLE bank, with timed test mode, tutor mode, and progress tracking by topic.
Practise the full bank